Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands

详细信息    查看全文

• 作者：Anouk Jochemsp>ap>p> ; p>p>1p> ; Maartje G. Schouwenburgp>ap>p> ; p>p>1p> ; Brenda Leenemanp>bp> ; Margreet G. Frankenp>bp> ; Alfons J.M. van den Eertweghp>cp> ; John B.A.G. Haanenp>dp> ; Hans Gelderblomp>ap> ; Carin A. Uyl-de Grootp>bp> ; Maureen J.B. Aartsp>ep> ; Franchette W.P.J. van den Berkmortelp>fp> ; Willeke A.M. Blokxp>gp> ; Mathilde C. Cardous-Ubbinkp>hp> ; Gerard Groenewegenp>ip> ; Jan Willem B. de Grootp>jp> ; Geke A.P. Hospersp>kp> ; Ellen Kapiteijnp>ap> ; Rutger H. Koornstrap>lp> ; Wim H. Kruitp>mp> ; Marieke W. Louwmanp>hp> ; Djura Piersmap>np> ; Rozemarijn S. van Rijnp>op> ; Albert J. ten Tijep>pp> ; Gerard Vreugdenhilp>qp> ; Michel W.J.M. Woutersp>rp> ; Jacobus J.M. van der Hoevenp>ap>p> ; p>p>J.J.M.van_der_Hoeven@lumc.nlp>
• 关键词：Quality assurance ; Metastatic melanoma ; Checkpoint inhibitors ; MAP kinase inhibitors ; Population-based ; Registry ; Ipilimumab
• 刊名：European Journal of Cancer
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：72
• 期：Complete
• 页码：156-165
• 全文大小：764 K
• 卷排序：72

文摘

This is the first multipurpose nationwide registry for metastatic melanoma. Collaboration of all stakeholders from the start has been the key to its success. Toxicity rates of the new drugs were consistent with the results of the pivotal trials. Median overall survival was 10.1 and 12.7 months in the first 2 registration years. The DMTR can be used as a blueprint for future real-world data initiatives.